Celcuity (CELC) Net Income towards Common Stockholders (2016 - 2026)
Celcuity's (CELC) quarterly Net Income towards Common Stockholders came in at -$51.0 million in Q4 2025, down 39.07% YoY from -$83.7 million in Q4 2024, and down 16.37% on a QoQ basis from -$43.8 million in Q3 2025.
Celcuity (CELC) Net Income towards Common Stockholders (2016 - 2026) Analysis & Trends
Celcuity (CELC) has 10 years of Net Income towards Common Stockholders data on file, last reported at -$51.0 million in Q4 2025.
- Quarterly Net Income towards Common Stockholders fell 39.07% year-over-year to -$51.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$177.0 million (down 58.39% YoY) and the FY2025 annual result came in at -$139.9 million, down 24.38% from the prior year.
- Net Income towards Common Stockholders retreated to -$51.0 million in Q4 2025, from -$43.8 million in the prior quarter.
- In the past five years, Net Income towards Common Stockholders ranged from a high of -$2.8 million in Q1 2021 to a low of -$51.0 million in Q4 2025.
- A 5-year average of -$21.1 million and a median of -$16.5 million in 2023 frame the typical range for Net Income towards Common Stockholders.
- Annual changes were most pronounced in 2021 — Net Income towards Common Stockholders slumped 1104.06% — and 2022, when it rose 29.02%.
- Tracing CELC's Net Income towards Common Stockholders over 5 years: stood at -$6.8 million in 2021, then plunged by 71.49% to -$11.6 million in 2022, then slumped by 62.75% to -$18.8 million in 2023, then plunged by 94.46% to -$36.7 million in 2024, then plunged by 39.07% to -$51.0 million in 2025.
- The last three Net Income towards Common Stockholders figures came in at -$51.0 million (Q4 2025), -$43.8 million (Q3 2025), and -$45.3 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 472.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 930.12 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Celcuity | 4.50 Bn | 4.50 Bn | - | -78.86 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -78.86 Mn |
| Dec 31, 2025 | -50.97 Mn |
| Sep 30, 2025 | -43.80 Mn |
| Jun 30, 2025 | -45.27 Mn |
| Mar 31, 2025 | -37.00 Mn |
| Dec 31, 2024 | -36.65 Mn |
| Sep 30, 2024 | -29.79 Mn |
| Jun 30, 2024 | -23.72 Mn |
| Mar 31, 2024 | -21.61 Mn |
| Dec 31, 2023 | -18.85 Mn |
| Sep 30, 2023 | -18.40 Mn |
| Jun 30, 2023 | -14.59 Mn |
| Mar 31, 2023 | -11.94 Mn |
| Dec 31, 2022 | -11.58 Mn |
| Sep 30, 2022 | -10.89 Mn |
| Jun 30, 2022 | -9.96 Mn |
| Mar 31, 2022 | -7.93 Mn |
| Dec 31, 2021 | -6.75 Mn |
| Sep 30, 2021 | -6.03 Mn |
| Jun 30, 2021 | -14.03 Mn |